180 related articles for article (PubMed ID: 15932522)
1. Cannabinoid influence on cytokine profile in multiple sclerosis.
Katona S; Kaminski E; Sanders H; Zajicek J
Clin Exp Immunol; 2005 Jun; 140(3):580-5. PubMed ID: 15932522
[TBL] [Abstract][Full Text] [Related]
2. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?].
Trebst C; Stangel M
Fortschr Neurol Psychiatr; 2005 Aug; 73(8):463-9. PubMed ID: 16052440
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid system and neuroinflammation: implications for multiple sclerosis.
Correa F; Docagne F; Mestre L; Loría F; Hernangómez M; Borrell J; Guaza C
Neuroimmunomodulation; 2007; 14(3-4):182-7. PubMed ID: 18073512
[TBL] [Abstract][Full Text] [Related]
4. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.
Aragona M; Onesti E; Tomassini V; Conte A; Gupta S; Gilio F; Pantano P; Pozzilli C; Inghilleri M
Clin Neuropharmacol; 2009; 32(1):41-7. PubMed ID: 18978501
[TBL] [Abstract][Full Text] [Related]
5. [Serum levels of interleukin-6 and interleukin-10 in patients with multiple sclerosis during intravenous immunoglobulin infusion].
Kazibutowska Z; Motta E; Huć M; Strzała-Orzeł M; Woźnik G
Wiad Lek; 2006; 59(9-10):626-9. PubMed ID: 17338118
[TBL] [Abstract][Full Text] [Related]
6. Cytokine levels in supernatants of whole blood and mononuclear cell cultures in adults and neonates reveal significant differences with respect to interleukin-13 and interferon-gamma.
Silberer J; Ihorst G; Kopp MV
Pediatr Allergy Immunol; 2008 Mar; 19(2):140-7. PubMed ID: 18257902
[TBL] [Abstract][Full Text] [Related]
7. Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
Prescrire Int; 2009 Oct; 18(103):226. PubMed ID: 19882800
[No Abstract] [Full Text] [Related]
8. Serum cytokine levels in response to hepatic cryoablation.
Osada S; Imai H; Tomita H; Tokuyama Y; Okumura N; Matsuhashi N; Sakashita F; Nonaka K
J Surg Oncol; 2007 May; 95(6):491-8. PubMed ID: 17219394
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
10. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection.
Lee N; Wong CK; Chan PK; Lun SW; Lui G; Wong B; Hui DS; Lam CW; Cockram CS; Choi KW; Yeung AC; Tang JW; Sung JJ
Clin Infect Dis; 2007 Sep; 45(6):723-31. PubMed ID: 17712756
[TBL] [Abstract][Full Text] [Related]
11. Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy.
Terenghi F; Allaria S; Nobile-Orazio E
J Peripher Nerv Syst; 2006 Mar; 11(1):67-71. PubMed ID: 16519784
[TBL] [Abstract][Full Text] [Related]
12. [Level of the cytokine secreted by periferal blood mononuclear cells in patients with chronic hepatitis C before antiviral therapy].
Dong Y; Zhang HF; Chen H; Li J; Yang XJ; Zhu SS; Cheng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Oct; 22(5):364-6. PubMed ID: 19469176
[TBL] [Abstract][Full Text] [Related]
13. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
[TBL] [Abstract][Full Text] [Related]
14. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
[TBL] [Abstract][Full Text] [Related]
15. Cannabis-based medicines in multiple sclerosis--a review of clinical studies.
Rog DJ
Immunobiology; 2010 Aug; 215(8):658-72. PubMed ID: 20541836
[TBL] [Abstract][Full Text] [Related]
16. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
Rog DJ; Nurmikko TJ; Friede T; Young CA
Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of interferon-gamma and interleukin-4, Th cell-derived cytokines by So-Shi-Ho-Tang (Sho-Saiko-To) occurs at the level of antigen presenting cells, but not CD4 T cells.
Kang H; Choi TW; Ahn KS; Lee JY; Ham IH; Choi HY; Shim ES; Sohn NW
J Ethnopharmacol; 2009 May; 123(1):6-14. PubMed ID: 19429332
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective agents: cannabinoids.
Sánchez AJ; García-Merino A
Clin Immunol; 2012 Jan; 142(1):57-67. PubMed ID: 21420365
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
Conte A; Bettolo CM; Onesti E; Frasca V; Iacovelli E; Gilio F; Giacomelli E; Gabriele M; Aragona M; Tomassini V; Pantano P; Pozzilli C; Inghilleri M
Eur J Pain; 2009 May; 13(5):472-7. PubMed ID: 18603457
[TBL] [Abstract][Full Text] [Related]
20. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
